Literature DB >> 3025510

Effect of angiotensin I converting enzyme inhibition on circulating atrial natriuretic peptide in humans.

F E Mann, R E Lang, M Leidig, E Ritz.   

Abstract

We investigated the effects of inhibition of angiotensin II (ANG II) formation with an ANG I converting enzyme inhibitor, namely Enalapril, on circulating levels of atrial natriuretic peptide (ANP). Seven normal volunteers received a low sodium diet in order to stimulate the renin-angiotensin system (period I). Subsequently, subjects maintained their low dietary sodium intake and received Enalapril perorally (period II). Each study period lasted for 6 days. Results indicated that subjects maintained a low dietary sodium intake with expected changes of the renin system before and during ANG I converting enzyme inhibition. Enalapril elicited a substantial fall in circulating ANP levels in six of the seven subjects studied. The causes of this change will have to be established but may possibly relate to hemodynamic consequences of Enalapril.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3025510

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  4 in total

1.  Early treatment with captopril after acute myocardial infarction.

Authors:  S G Ray; M Pye; K G Oldroyd; J Christie; D T Connelly; D B Northridge; I Ford; J J Morton; H J Dargie; S M Cobbe
Journal:  Br Heart J       Date:  1993-03

Review 2.  Atrial natriuretic peptide. An overview of clinical pharmacology and pharmacokinetics.

Authors:  A C Tan; F G Russel; T Thien; T J Benraad
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

3.  Influence of angiotensin converting enzyme inhibition on relation of atrial natriuretic peptide concentration to atrial pressure in heart failure.

Authors:  H Berglund; O Nyquist; B Beermann; M Jensen-Urstad; E Theodorsson
Journal:  Br Heart J       Date:  1994-12

4.  The effect of acute ACE inhibition on atrial natriuretic peptide.

Authors:  C J Doorenbos; P van Brummelen
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.